Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 936 trials

Haemophilia A: Inno8 Medication Study

We are researching how different doses of the medication Inno8 work in people with haemophilia A. This study aims to understand its effects on the body.

Haemophilia A6-12 monthsSafety phase (I)Hematology

Neurogenic Inflammation: TRPA1 Activation Study

We are investigating how a specific compound affects inflammation in people with conditions related to nerve pain. This research may help us understand better ways to manage pain and inflammation.

Healthy Participants3-6 monthsSafety phase (I)

Asthma Treatment: AMG 691 Study

We are testing a new medication called AMG 691 in healthy individuals and those with mild-to-moderate asthma. The goal is to see how it compares to a placebo in managing asthma symptoms.

Asthma1-2 yearsSafety phase (I)Internal MedicinePulmonology

Plaque Psoriasis and Eczema: RLS-1496 Cream

We are testing a new topical cream for patients with plaque psoriasis or eczema. The goal is to see how safe it is and how well it works compared to existing treatments.

Atopic DermatitisPsoriasis6-12 monthsSafety phase (I)AllergologyDermatology

Advanced Solid Tumors: SNV1521 Treatment Study

We are exploring a new treatment called SNV1521 for individuals with advanced solid tumors. This study aims to determine the safety and appropriate dosage of this medication.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

PF-07940369: Tolerance Study in Healthy Adults

We are investigating how well different amounts of the medicine PF-07940369 are tolerated by healthy adults. This study will help us understand its effects in the body.

Clonal Hematopoiesis6-12 monthsSafety phase (I)Hematology

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

HIV Treatment: New Antibody Study

We are investigating whether adding a new antibody to current HIV medications helps reduce the viral reservoir in adults living with HIV. This study aims to improve treatment outcomes for those affected.

HIV Infection>2 yearsSafety phase (I)Infectious DiseasesInternal Medicine

Healthy Volunteers Needed: Itraconazole and BI 3031185 Study

We are testing how itraconazole affects the levels of BI 3031185 in the blood of healthy participants. This study aims to improve our understanding of drug interactions.

Healthy Volunteers≤3 monthsSafety phase (I)DermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

Healthy Volunteers Needed: BI 3000202 Interaction Study

We are testing how the new medication BI 3000202 affects the absorption of rosuvastatin and digoxin in healthy people. This research aims to improve our understanding of these drug interactions.

Healthy VolunteersSafety phase (I)Internal Medicine

Gene Therapy for Vision Loss: SPVN20 Study

We are testing a new gene therapy for people with no light perception due to end-stage rod cone dystrophy. The study aims to assess the safety and tolerability of a single injection in those who still have dormant cone photoreceptors.

Hereditary Retinal DystrophyEnd-stage Rod-Cone DystrophySafety phase (I)Ophthalmology

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cemiplimab and Imiquimod for High-Risk Basal Cell Carcinoma

We are studying a combination of cemiplimab, imiquimod, and laser therapy for patients with high-risk cutaneous basal cell carcinoma. The goal is to evaluate safety and how well this treatment works before surgery.

Skin Cancer (Basal Cell Carcinoma)>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Kidney Health: BIA 28-6156 Study

We are evaluating a new medication for people with varying degrees of kidney impairment. The study focuses on its safety and how the body processes it.

Parkinson's Disease6-12 monthsSafety phase (I)NephrologyNeurology

Etrasimod in Breastfeeding Women

We are studying how the medication etrasimod is absorbed into the blood and breast milk of healthy lactating women. This research will help us understand its safety and potential effects on breastfeeding infants.

Ulcerative Colitis1-2 yearsSafety phase (I)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics

JNJ-90106848: Safety and Body Response Study

We are evaluating a new drug to see how safe it is and how it works in healthy volunteers. This study will help us understand how long the drug stays in the body and how the body reacts to it.

Inflammatory ConditionsSafety phase (I)AllergologyInfectious Diseases

Icotrokinra: Understanding Its Effects in Healthy Volunteers

We are exploring how long icotrokinra stays in the body and how it works when taken as different tablet types and with various foods. This research aims to improve our understanding of the medication's behavior.

Inflammatory ConditionsSafety phase (I)Infectious DiseasesInternal Medicine

Pomalidomide for Chronic Hepatitis B Infection

We are studying the safety of pomalidomide in people with chronic hepatitis B. The trial also looks at how this medication may improve immune responses and liver health.

Hepatitis B Virus Infection6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHepatologyInfectious Diseases